Cargando…
Clinically available RNA profiling tests of prostate tumors: utility and comparison
In the postscreening era, physicians are in need of methods to discriminate aggressive from nonaggressive prostate cancer (PCa) to reduce overdiagnosis and overtreatment. However, studies have shown that prognoses (e.g., progression and mortality) differ even among individuals with similar clinical...
Autores principales: | Na, Rong, Wu, Yishuo, Ding, Qiang, Xu, Jianfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955181/ https://www.ncbi.nlm.nih.gov/pubmed/26975490 http://dx.doi.org/10.4103/1008-682X.175096 |
Ejemplares similares
-
Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016) -
Age-Specific Prostate Specific Antigen Cutoffs for Guiding Biopsy Decision in Chinese Population
por: Na, Rong, et al.
Publicado: (2013) -
Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases
por: Na, Rong, et al.
Publicado: (2016) -
Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011
por: Na, Rong, et al.
Publicado: (2012) -
The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer
por: Xu, Jianfeng
Publicado: (2014)